| Heading: |
Tirzepatide: Primary Care |
| Question ID: |
1819992 |
| UIN: |
HL9195 |
| House: |
Lords |
| Date tabled: |
2025-07-07 |
| Asking Member ID: |
4130 |
| Asking Member display name: |
Baroness Ritchie of Downpatrick
|
| Asking Member handle: |
MRitchieSD
|
| Asking Member Twitter reference: |
@MRitchieSD
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what steps they are taking to ensure GPs are prepared to coordinate medicines management and understand the side effects of receiving weight loss medication as a result of the roll-out of tirzepatide (Mounjaro) in primary c |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-11 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
From 23 June, tirzepatide, brand name Mounjaro, started to become available in primary care, in line with the agreed plans for a phased rollout, meaning it can be prescribed in general practices. The National Institute for Health and Care Excellence (NICE... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |